-transparent.png){kind=logo}
A controlled clinical trial compared three-drug and four-drug combination chemotherapy in 109 patients with advanced small-cell anaplastic carcinoma of the lung. The combination of vincristine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), cyclophosphamide, and methotrexate was significantly superior to the combination of the last three drugs alone with regard to median survival (230 versus 176 days) (P less than 0.01) and to duration of response (186 versus 112 days) (P less than 0.01). Objective response occurred in 78% and 75%, respectively. No significant difference in these values was observed in the comparison of the three subtypes of small-cell anaplastic carcinoma using the World Health Organization classification.
H H Hansen, and
P Dombernowsky, and
M Hansen, and
F Hirsch
June 1982,
Cancer,
H H Hansen, and
P Dombernowsky, and
M Hansen, and
F Hirsch
January 1987,
Cancer chemotherapy and pharmacology,
H H Hansen, and
P Dombernowsky, and
M Hansen, and
F Hirsch
August 1979,
Cancer,
H H Hansen, and
P Dombernowsky, and
M Hansen, and
F Hirsch
April 1995,
Lung cancer (Amsterdam, Netherlands),
H H Hansen, and
P Dombernowsky, and
M Hansen, and
F Hirsch
June 1982,
Cancer,
H H Hansen, and
P Dombernowsky, and
M Hansen, and
F Hirsch
April 1983,
Acta medica Okayama,
H H Hansen, and
P Dombernowsky, and
M Hansen, and
F Hirsch
June 1985,
Cancer treatment reports,
H H Hansen, and
P Dombernowsky, and
M Hansen, and
F Hirsch
April 1976,
JAMA,
H H Hansen, and
P Dombernowsky, and
M Hansen, and
F Hirsch
August 1975,
Cancer,
H H Hansen, and
P Dombernowsky, and
M Hansen, and
F Hirsch
February 1987,
La Clinica terapeutica,
